Novel Highly Tumour-restricted Antigens and Antibodies for Cancer Therapy

Cumulus Oncology identifies and funds the progression of early-stage opportunities to develop novel differentiated anti-cancer therapies, with the aim of improving outcomes for cancer patients. They are interested in identifying and engaging with academics who have highly tumour-restricted antigens or monoclonal or multivalent antibodies that target them which have the potential for therapeutic activity in cancer.

Approaches of Interest:

• Novel monoclonal antibodies, bi- and / or tri-specific antibodies that bind highly tumour-restricted antigens which ...